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Background: Hyperglycemia, a risk factor for development of cardiovascular disease, causes endothelial
dysfunction. Alpha-glucosidase inhibitors (α-GIs) improve postprandial hyperglycemia (PPHG) and may have
favorable effects on associated cardiovascular disease. Effects of α-GIs in patients with acute coronary syndrome
(ACS) and PPHG remain unclear; thus, we assessed the effect of α-GI miglitol on endothelial function in such
patients by digital reactive hyperemia peripheral arterial tonometry (RH-PAT).
Methods: Fifty-four patients with ACS who underwent primary percutaneous coronary intervention were enrolled
in the study: 36 with new-onset PPHG and 18 with normal glucose tolerance. Eighteen PPHG patients were given
50 mg of miglitol with each meal for 1 week. Endothelial function was assessed on the basis of the RH-PAT index
(RHI) before and after the 1-week miglitol treatment. The other 18 PPHG patients and the 18 NGT patients were not
given any anti-diabetic agent for 1 week, and endothelial function was assessed.
Results: Postprandial RHI decreased significantly in patients with PPHG. Miglitol improved PPHG significantly;
postprandial RHI also improved (p = 0.007). Significant inverse correlation was found between the postprandial
change in RHI and postprandial fasting-to-60-minutes surge in glucose (r = −0.382, p = 0.009). Moreover, the
improvement in endothelial function correlated with the reduced postprandial glucose surge achieved with miglitol
(r = −0.462, p = 0.001).
Conclusions: Postprandial changes in glucose are related to endothelial dysfunction in ACS. Miglitol-based
improvement in PPHG appears to improve endothelial function. The effect of miglitol on glucose-dependent
endothelial function might improve outcomes of ACS.
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Several studies have surprisingly shown that intensive
glycemic control with insulin or sulfonylurea does not
reduce the mortality associated with cardiovascular
events in persons with diabetes [1-3]. Furthermore, car-
diovascular morbidity and overall mortality are associ-
ated with postprandial hyperglycemia (PPHG) rather
than the fasting blood glucose level [4-6], and chronic
hyperglycemia induces endothelial dysfunction [7-9]. In
animal studies, repetitive PPHG has been shown to pro-
duce endothelial dysfunction and increase cardiac ische-
mia and reperfusion injury [10-12]. In addition, vascular
endothelial dysfunction contributes to cardiovascular
events and can be useful for identifying patients at high
risk for ischemic heart disease [13-15]. Thus, PPHG may
cause endothelial dysfunction and subsequent athero-
sclerosis, increasing the risk of cardiovascular events.
However, it remains unclear whether PPHG actually
worsens endothelial function of patients with acute cor-
onary syndrome (ACS).
Alpha-glucosidase inhibitors (α-GIs) competitively and
reversibly inhibit intestinal membrane-bound α-glucosidase
required for degradation of disaccharides and complex car-
bohydrates in the upper part of the small intestine [16-18].
The effect of α-GIs on the intestinal membrane manifests
as a reduction in PPHG. Thus, treatment with α-GI
acarbose might have a favorable effect on endothelial func-
tion in type 2 diabetes patients with ischemic heart disease
[19-22]. Miglitol is an α-GI with unique pharmacokinetic
properties. It is absorbed rapidly and almost completely
from the small intestine after oral administration. In an ani-
mal study, miglitol was shown to reduce myocardial infarct
size [23]. Moreover, vascular function of patients improved
when miglitol was administrated repeatedly [24]. Thus,
compared to other α-GIs, miglitol can be expected to
suppress PPHG more strongly and thereby reduce the
incidence of cardiovascular events. However, little is ac-
tually known regarding the specific effects of miglitol
on postprandial glycemia and endothelial function in
patients with ACS.
We investigated endothelial function in patients with
and without PPHG who had undergone primary percutan-
eous coronary intervention (PCI) for ACS. We then
assessed the effects of miglitol on postprandial glycemia
and endothelial function in the ACS patients with PPHG.
Methods
Study participants
We recruited 54 ACS patients, aged 20 to 79 years, who
underwent successful primary PCI at Nihon University
Itabashi Hospital, Tokyo, Japan, between April 1, 2009
and March 31, 2011. The patients were not previously
diagnosed with type 1 (insulin-dependent) or type 2 dia-
betes mellitus (DM), not previously treated with insulinor oral anti-diabetic agents, not on diet therapy, and
without a hemoglobin A1c (HbA1c) level > 7.9% (NGSP
units) or fasting blood glucose > 200 mg/dL. Patients
with severe myocardial infarction, heart failure, severe
hepatic disease, renal insufficiency (serum creatinine > 2
mg/dL or treatment by hemodialysis), or collagen disease
patients were excluded. The 54 enrolled patients were
diagnosed as having (n = 36) or not having (n = 18)
PPHG, i.e., normal glucose tolerance (NGT), according
the postprandial glucose level at 60 minutes after loading
of a test meal. PPHG was defined as a postprandial glu-
cose level ≥ 130 mg/dL at 60 minutes. The test meal was
that recommended by the Japan Diabetes Society work-
ing group [25] and consisted of 56.5 g of carbohydrate,
16.0 g of protein, and 18.0 g of fat for a total 460 kcal of
energy (Kewpie, Tokyo, Japan). The test meal was served
with a 100-mL glass of water and ingested within 15 mi-
nutes. Yoshino et al. reported that the peak glucose level
is reached 60 minutes after test meal loading, and that
the glucose level at 60 minutes after test meal loading
correlated with that at 120 minutes after glucose loading.
A blood glucose value of 140 mg/dL at 120 minutes after
glucose loading corresponds to 130 mg/dL at 60 minutes
after test meal loading [25-27]. Thus, PPHG was defined
as a postprandial glucose level ≥ 130 mg /dL at 60 mi-
nutes after test meal loading. For all patients enrolled,
previously prescribed medications and daily diet were
maintained throughout the study period. The study was
approved by the Ethics Committee of Nihon University
School of Medicine, and all participants provided written
informed consent.
Study design
The study was a 1-week, randomized, single-blind con-
trolled clinical trial. As shown in Figure 1, a baseline
dietary tolerance test predicated on the test meal was
performed 1 week after successful primary PCI to avoid
any possible influence of ACS on dietary tolerance. All
vasoactive medications were discontinued at least 12
hours prior to the test, and the test meal was given after
a 12-hour overnight fast. We evaluated several biochem-
ical markers associated with metabolism, inflammation,
oxidative stress, and endothelial function in the fasting
state and at 60 minutes and 120 minutes after test meal
loading. The patients with PPHG were randomly divided
into two groups; a PPHG-miglitol group (n = 18) that
was given 50 mg of miglitol three times a day with each
meal for 1 week and a PPHG-control group (n = 18) that
was not given miglitol or any other anti-diabetic agent
for 1 week. Upon completion of the 1-week miglitol
intervention/non-intervention (control), the dietary tol-
erance test was repeated, and blood biochemical markers
and endothelial function were re-assessed. The 18

























1 week after primary PCI
First test meal loading
and RH-PAT
2 weeks after primary PCI
Second test meal loading
and RH-PAT
Figure 1 Study flowchart. ACS acute coronary syndrome, PCI percutaneous coronary intervention, BGL blood glucose level, PPHG postprandial
hyperglycemia, NGT normal glucose tolerance, DM: diabetes mellitus, RH-PAT reactive hyperemia peripheral arterial tonometry.
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re-assessment of blood biochemical markers and endo-
thelial function.Laboratory tests
Standard blood samples were drawn in the fasting state
to measure HbA1c, 1,5-anhydro-D-glucitol (1,5-AG),
glycated albumin (GA), total cholesterol (T-CHOL), low-
density lipoprotein-cholesterol (LDL-C), high-density li-
poprotein-cholesterol (HDL-C), creatine phosphokinase
(CPK), serum creatinine, estimated glomerular filtration
rate (eGFR), and N-terminal prohormone of brain natri-
uretic peptide (NT-proBNP). Insulin resistance was eval-
uated by means of homeostasis model assessment of
insulin resistance (HOMA-IR).
Plasma glucose, serum insulin, triglyceride (TG), high
sensitivity C-reactive protein (hs-CRP), and derivatives
of reactive oxidative metabolites (d-ROMs) as an oxida-
tive stress marker measured with a free radical analytical
system (FRAS4; H-&-D srl, Parma, Italy) [28] were mea-
sured in the fasting state and at 60 minutes and 120 mi-
nutes after test meal loading.
We also assessed incretins glucagon-like petide-1
(GLP-1) and glucose-dependent insulinotropic polypep-
tide (GIP) in the fasting state and at 60 minutes and 120
minutes after test meal loading. Blood samples were col-
lected from 8 patients in the PPHG-miglitol group and 8
patients in the NGT group, and 10 μL of dipeptidyl
peptidase-4 inhibitor per 1 mL blood was added imme-
diately. The blood samples were centrifuged at 1,000 x g
for 10 minutes under refrigeration. Total GLP-1 (9–36)
was measured with an enzyme-linked immunosorbent
assay (ELISA) kit (ALPCO Diagnostics Inc., Salem, NH,
USA) and total GIP was measured with an ELISA kit
(Millipore Corp., Billerica, MA, USA).Assessment of endothelial function
Endothelial function was evaluated in the fasting state
and at 60 minutes and 120 minutes after test meal load-
ing by digital reactive hyperemia peripheral arterial to-
nometry (RH-PAT) (Endo-PAT 2000, Itamar Medical
Ltd., Caesarea, Israel). RH-PAT was performed as previ-
ously described [29,30]. Briefly, a blood pressure cuff
was placed on the participant’s upper right arm; the left
arm was used for control. A PAT probe was placed on
the right and left forefingers. The RH-PAT protocol
began with a 5-minute baseline measurement. The cuff
on the test arm was then inflated to 60 mmHg above the
baseline systolic pressure or to at least 200 mmHg for 5
minutes. The cuff was then deflated to induce RH. The
RH-PAT data were digitally analyzed online (Endo-PAT
2000 software, ver. 3.0.4). The RH-PAT index (RHI),
which reflects the extent of reactive hyperemia, was cal-
culated as the ratio of the average amplitude of the
PAT signal over 1 minute, starting 1.5 minutes after cuff
deflation (occluded arm, A; control arm, C), divided by
the average amplitude of the baseline PAT signal over a
2.5-minute period before cuff inflation (occluded arm, B;
control arm, D). Thus, RHI = (A/B)/(C/D).Statistical analysis
Continuous variables are presented as mean ± SEM; dis-
orders, e.g., hypertension, are presented as the number
and percentage of patients affected; and use of various
medications is presented as the number and percentage
of patients receiving them. Between-group differences in
data were subjected to one-way analysis of variance
(ANOVA). Between-group differences in the prevalence
of risk factors and use of medications were analyzed by
chi-square test. Two-way ANOVA with repeated mea-
sures followed by Tukey’s post hoc test was used to detect
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determined by linear regression analysis. All statistical
analyses were performed with JMP, ver. 9 (SAS Institute,
Cary, NC, USA). p < 0.05 was considered statistically
significant.
Results
Baseline patient characteristics and blood test results
Baseline characteristics and laboratory values of patients
are shown per study group in Table 1. There was no
statistical between-group difference in age; sex; body
mass index (BMI); prevalence of hypertension, hyperlip-




Age (years) 60.6 ± 2.1
Sex, male, n (%) 15 (83.3)
Body mass index (kg/m2) 25.1 ± 0.5
Hypertension, n (%) 15 (83.3)
Dyslipidemia, n (%) 15 (83.3)
Smoking, n (%) 12 (66.6)
Chronic kidney disease, n (%) 4 (22.2)
Laboratory values
Hemoglobin (mg/mL) 13.6 ± 0.3
Creatinine (mg/mL) 0.82 ± 0.04
eGFR (mL/min/1.73m2) 69.5 ± 3.5
Hemoglobin A1c (%) 6.4 ± 0.1*
1,5-AG (μg/mL) 11.4 ± 1.1**
Glycated albumin (%) 15.4 ± 0.4*
HOMA-IR 2.69 ± 0.38*
Total cholesterol (mg/dL) 196.0 ± 12.2
HDL cholesterol (mg/dL) 45.8 ± 2.1
LDL cholesterol (mg/dL) 126.6 ± 12.0
Creatine phospho-kinase (max) (IU/L) 2360.6 ± 465.2
NT-proBNP (pg/mL) 666.3 ± 280.5
Medications being used
Calcium channel blockers, n (%) 4 (22.2)
Beta blockers, n (%) 12 (66.7)
ACE-Is or ARBs, n (%) 13 (72.2)
Nitrates, n (%) 11 (61.1)**
Statins, n (%) 15 (83.3)
Data are expressed as mean ± SEM or number and percentage of patients. *p < 0.05
PPHG-control vs. NGT; ††p < 0.01, PPHG-control vs. NGT.
PPHG-miglitol group: patients with postprandial hyperglycemia given miglitol for 1
NGT group: patients with normal glucose tolerance; eGER: estimated glomerular filt
assessment of insulin resistance; HDL: high density lipoprotein; LDL: low density lip
ACE-I: angiotensin converting enzyme inhibitor; ARB: angiotensin II receptor blockeThere was no significant difference in the use of most
medications (calcium channel blockers, beta blockers,
angiotensin II receptor blockers [ARBs]/angiotensin con-
verting enzyme inhibitors [ACE-Is], or statins). Neither was
there any between-group difference in the hemoglobin,
serum creatinine, eGFR, T-CHOL, HDL-C, LDL-C, TG,
CPK, or NT-proBNP level. Use of nitrates, including
nicorandil, was more prevalent in the NGT group than in
the PPHG groups. The baseline HbA1c, GA, and HOMA-
IR levels were significantly higher and the 1,5-AG level
was significantly lower in the patients with PPHG than in
the NGT patients. As expected, fasting plasma glucose
levels were significantly higher in the patients withPPHG-control NGT
n = 18 n = 18
65.1 ± 2.2 60.3 ± 2.1
14 (77.8) 16 (88.9)
25.0 ± 0.7 25.3 ± 0.5
16 (88.9) 16 (88.9)
14 (77.8) 14 (77.8)
11 (61.1) 10 (55.6)
5 (27.8) 7 (38.9)
13.2 ± 0.2 13.1 ± 0.3
0.85 ± 0.04 1.01 ± 0.06
70.7 ± 2.6 63.1 ± 3.5
6.5 ± 0.1† 5.6 ± 0.1
11.5 ± 1.0†† 20.8 ± 1.8
15.2 ± 0.5† 14.2 ± 0.3
2.22 ± 0.47† 1.69 ± 0.17
195.5 ± 8.2 202.1 ± 7.1
47.0 ± 2.1 46.0 ± 2.5
125.3 ± 7.6 136.3 ± 5.7
2453.3 ± 487.6 3174.7 ± 626.2
664.9 ± 238.6 616.7 ± 279.9
8 (44.4) 6 (33.3)
8 (44.4) 18 (44.4)
12 (66.7) 12 (66.7)
12 (66.7)†† 18 (100)
14 (77.8) 14 (77.8)
, PPHG-miglitol vs. NGT; **p < 0.01, PPHG-miglitol vs. NGT; †p < 0.05,
week; PPHG-control group: patients with PPHG not given miglitol for 1 week;
ration rate; 1,5-AG: 1,5-anhydro-D-glucitol; HOMA-IR: homeostasis model
oprotein; NT-proBNP: N-terminal prohormone of brain natriuretic peptide;
r.
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Table S1). However, no differences in fasting serum in-
sulin, TG, and oxidative stress marker d-ROMs were
noted between groups. In addition, the fasting RHI did
not differ between groups (Additional file 1: Table S1).
There were no differences in baseline patient charac-
teristics or biochemical markers between the PPHG-
miglitol group and the PPHG-control group.Postprandial changes in blood glucose and insulin
Plasma glucose levels and serum insulin levels after over-
night fasting and at 60 minutes and 120 minutes after the
test meal are shown in Figure 2 and Additional file 2:
Figure S1. With miglitol administration, postprandial
plasma glucose levels were decreased significantly at 60 and
120 minutes after the test meal (from 175.2 ± 4.9 mg/dL to
132.2 ± 4.8 mg/dL at 60 minutes, p < 0.001; from 171.5 ±
6.6 mg/dL to 137.1 ± 6.1 mg/dL at 120 minutes, p < 0.001;
Figure 2A), and postprandial serum insulin levels were
also decreased significantly (from 47.1 ± 5.2 μU/mL to
27.0 ± 6.1 μU/mL at 60 minutes, p = 0.031; from 56.6 ±
5.8 μU/mL to 34.1 ± 5.5 μU/ml at 120 minutes, p = 0.015;
Figure 2B). Plasma glucose levels and serum insulin
levels improved significantly in the PPHG-miglitol
group compared to those in the PPHG-control group. InFigure 2 Changes in plasma glucose levels (A), serum insulin levels (B
and after the 1-week intervention (miglitol)/non-intervention (control
vs. PPHG-miglitol after; **p < 0.01, PPHG-miglitol before vs. PPHG-miglitol a
PPHG-miglitol after vs. PPHG-control after.RHI: RH-PAT index; PPHG: postpra
miglitol administration; PPHG-miglitol after: patients with PPHG given 50 m
PPHG before non-intervention; PPHG-control after; patients with PPHG aftethe PPHG-control group and the NGT group, there were
no significant time-specific changes in glucose or insulin
levels between time point (Figure 2A and B, and Additional
file 2: Figure S1A and B).
Postprandial changes in lipids, oxidative stress and
inflammatory markers
The postprandial TG levels increased gradually in both
the PPHG-miglitol group and the PPHG-control group
with no between-group-difference (Figure 2C). There
was no statistical difference in the postprandial TG or
d-ROMs levels either before or after 1-week therapy be-
tween the PPHG-miglitol group and PPHG-control
group (Figure 2C and 3A). However, in the NGT group,
there was a significant time-specific decrease in the
fasting d-ROMs level (from 469.8 ± 14.6 U.CARR to 367.0 ±
24.5 U.CARR, p = 0.004; Additional file 1: Table S1).
Furthermore, the fasting hs-CRP level in the PPHG-
miglitol group decreased significantly (from 0.778 ±
0.105 mg/dL to 0.359 ± 0.094 mg/dL, p = 0.001), and it
also decreased significantly compared to that in the
PPHG-control group (p = 0.005) (Figure 3B).
Postprandial changes in endothelial function
Baseline fasting RHI in the NGT group was 1.62 ± 0.07,
and neither RHI at 60 minutes (1.61 ± 0.08) nor RHI at), triglyceride levels (C), and RHI (D) in the PPHG groups, before
). Data are expressed as mean ± SEM. *p < 0.05, PPHG-miglitol before
fter; †p < 0.05, PPHG-miglitol after vs. PPHG-control after; ††p < 0.01,
ndial hyperglycemia; PPHG-miglitol before: patients with PPHG before








Figure 3 Fasting d-ROMs levels (A), fasting hs-CRP levels (B),
and postprandial percent changes in RHI (C) in the PPHG
groups, before and after the 1-week intervention (miglitol)/
non-intervention (control). Data are expressed as mean ± SEM.
d-ROMs: derivatives of reactive oxidative metabolites; hs-CRP: high
sensitivity C-reactive protein; RHI: RH-PAT index; PPHG: postprandial
hyperglycemia; PPHG-miglitol before: patients with PPHG before
miglitol administration; PPHG-miglitol after: patients with PPHG
given 50 mg of miglitol every meal for 1 week; PPHG-control before:
patients with PPHG before non-intervention; PPHG-control after;
patients with PPHG after 1-week non-intervention; postprandial
percent change in RHI: (120 minutes RHI – fasting RHI)/fasting
RHI × 100; NS: not significant.
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(p = 0.834 and p = 0.285, respectively) (Additional file 2:
Figure S1D). Nor was there a significant change in post-
prandial endothelial function after the experimental week.In other words, postprandial endothelial function was not
significantly impaired in this group.
RHI did change significantly, however, in patients with
PPHG (Figure 2D). In the PPHG-miglitol group, post-
prandial RHI decreased significantly from a baseline
value of 1.56 ± 0.06 to 1.43 ± 0.07 by 60 minutes, and to
1.37 ± 0.06 by 120 minutes (p = 0.040 and p = 0.002, re-
spectively). In the PPHG-control group, RHI also de-
creased significantly from a baseline value of 1.49 ± 0.13
to 1.41 ± 0.10 by 60 minutes, and to 1.41 ± 0.09 by 120
minutes (p = 0.049 and p = 0.048, respectively). RHI
values at 60 minutes and 120 minutes were decreased
significantly in patients with PPHG in comparison to the
values in the NGT patients, suggesting significantly im-
paired postprandial endothelial function in both PPHG
groups.
After miglitol administration, the fasting RHI was de-
creased at 60 minutes (from 1.53 ± 0.07 upon fasting to
1.37 ± 0.19 at 60 minutes, p = 0.019) but was restored to
above the fasting level by 120 minutes (from 1.37 ± 0.07 to
1.56 ± 0.09, p = 0.031), and it improved significantly com-
pared to that in the PPHG-control group (p = 0.041). We
also evaluated postprandial endothelial function as percent
change in RHI: [(120 minutes RHI – fasting RHI)/fasting
RHI × 100]. The percent postprandial change in RHI was
significantly suppressed after miglitol administration in
the PPHG-miglitol group compared to that in the same
group before miglitol administration and that in the
PPHG-control group at 1 week (p = 0.007, p = 0.031, re-
spectively; Figure 3C).
Postprandial changes in incretins
We assessed incretins total GLP-1 and total GIP in the
most recently enrolled patients in the PPHG-miglitol
group (n = 8) and the NGT group (n = 8). After miglitol
administration, total GLP-1 was significantly increased
60 minutes after the test meal (from 3.77 ± 0.43 pmol/L
upon fasting to 4.58 ± 0.13 pmol/L at 60 minutes, p = 0.048;
Additional file 3: Figure S2A). Moreover, the total GIP level
was significantly decreased in patients in the PPHG-
miglitol group 60 minutes after the test meal (from
514.7 ± 95.8 pg/mL upon fasting to 289.4 ± 58.6 pg/mL
at 60 minutes, p = 0.006; Additional file 3: Figure S2B).
Major determinant of postprandial endothelial function
No significant relation was found between fasting RHI
and any other variable (age, sex, BMI, or level of serum
creatinine, eGFR, HbA1c, 1,5-AG, GA, HOMA-IR, T-
CHOL, HDL-C, LDL-C, CPK, NT-proBNP and fasting
plasma glucose, serum insulin, TG, hs-CRP, or d-ROMs).
To clarify the determinants of postprandial endothelial
dysfunction, we assessed relations between the postpran-
dial change in RHI and other variables (age, sex, BMI, or
level of serum creatinine, eGFR, HbA1c, 1,5-AG, GA,
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and postprandial changes in plasma glucose, serum insu-
lin, TG, hs-CRP, and d-ROMs). The postprandial decrease
in RHI correlated with the fasting-to-60-minutes surge in
plasma glucose (r = −0.382, p = 0.009; Figure 4A), but no
correlations was observed between the change in RHI and
any other variable. In addition, we investigated correlation
between the improved postprandial change in RHI and
changes in other postprandial variables. Significant correl-
ation was found between the postprandial improvement in
RHI and the reduction in fasting-to-60-minutes glucose
surge by miglitol administration (r = −0.462, p= 0.001;
Figure 4B).
Discussion
This is the first study to evaluate postprandial endothe-
lial function on the basis of RHI in PPHG and NGT
patients with early-phase ACS. It is also the first to in-
vestigate the effect of α-GI miglitol on RHI-determined
postprandial endothelial function in ACS patients. Type
2 DM is a major risk factor for cardiovascular events
[31-33]. However, several studies have shown that
PPHG, more than impaired fasting glucose, is related to
endothelial dysfunction and cardiovascular risk [4,34-39].
Impaired glucose tolerance is also known to cause ACS
[40,41]. Vascular endothelial dysfunction may affect the
initiation and progression of arteriosclerosis and cause
coronary artery disease [42]. Postprandial hyperglycemic
spikes have been suggested to induce endothelial dysfunc-
tion through an increase in hyperglycemia-induced oxida-
tive stress. This may reduce production and bioavailability
of nitric oxide (NO), since hyperglycemia-induced endo-
thelial dysfunction is counterbalanced by arginine [43].
Previous studies have shown that oxygen-derived free rad-
icals interfere with or destroy endothelium-dependent
vasodilation by inactivating NO in normal vessels. In other
words, a rapid glucose surge injures endothelial cells andA
r = -0.382
p = 0.009
Figure 4 Correlation between postprandial percent change in RHI an
before intervention (A), and in the PPHG-miglitol group before and a
significant inverse correlation between postprandial change in RHI and pos
there was a significant correlation between improvement in endothelial fusuppresses NO production [44-47]. Results of the STOP-
NIDDM trial, which showed that α-GIs reduce the inci-
dence of cardiovascular events even in patients with im-
paired glucose tolerance, suggest the clinical importance
of interfering with postprandial changes in glucose [19].
Thus, because repetitive PPHG is thought to cause cardio-
vascular events [46,48], ameliorating PPHG may affect
endothelial function and prevent cardiovascular events
[22,38,46]. In the present study, we observed a significant
inverse correlation between postprandial endothelial func-
tion and PPHG. Thus, it is reasonable to think that ameli-
oration of PPHG would play an important role in
endothelial function. There were no postprandial changes
in oxidative stress marker d-ROMs and no relation be-
tween the RHI and d-ROMs. However, d-ROMs remained
higher in both PPHG groups than in the NGT group
under the experimental conditions, suggesting that with
repetitive PPHG, there is more exposure to oxidative
stress. Hyperinsulinemia and insulin resistance have also
been shown to cause endothelial dysfunction and to be
risk factors for atherosclerosis [46,49-52]. However, the in-
creased insulin after test meal loading may not have
played an important role in the acute induction of endo-
thelial dysfunction in our patients. We did not find a sig-
nificant relation between the RHI and the serum insulin
levels in our patients. Furthermore, our study did not
show any relation between endothelial function and insu-
lin resistance.
Evaluation of coronary endothelial function has made
it possible to predict cardiovascular events. However,
most of the evaluation methods used are invasive
[53,54]. PAT can be used to noninvasively evaluate the
endothelial function of resistance arteries and changes in
the flow response resulting from endothelial-derived
vasoactive substances including NO [55,56]. NO is an
important factor contributing to augmentation of the
PAT pulse amplitude after ischemia, and administrationB
r = -0.462
p = 0.001
d postprandial change in plasma glucose in the three groups
fter miglitol treatment (B). Linear regression analysis revealed a
tprandial change in the glucose level (A). In the PPHG-miglitol group,
nction and the reduction in glucose surge (B).
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sponse detected by PAT [56]. In addition, assessment by
RH-PAT is independent of the examiner, and the probes
are simply applied to the patient’s forefingers, one for
control measurements. Moreover, the measured values
are not affected by the autonomic nervous system. Previ-
ous studies have shown that measurement of endothelial
dysfunction assessed by RH-PAT is related to cardiovas-
cular risk [30] and that RH-PAT can be used to predict
coronary endothelial dysfunction [15]. This makes it
valuable for predicting coronary artery disease and car-
diovascular events [15,57,58]. Because RH-PAT is a non-
invasive, quantitative, and repeatable test, RH-PAT can
serve as an important surrogate marker testing method
for evaluating a patient’s vascular condition and the effi-
cacy of treatment. The present study confirmed that
RH-PAT measurements reflect coronary endothelial
function after ACS. The fasting baseline RHI in our
three patient groups was decreased significantly com-
pared to the cutoff value (1.67), suggesting that endothe-
lial function in patients with ACS is impaired. However,
ACS did not influence postprandial endothelial function
specifically, i.e., there were no time-specific changes
under the experimental conditions. Moreover, we found
a significant inverse correlation between postprandial
endothelial function and PPHG, i.e., amelioration of
postprandial glucose elevation suppressed postprandial
endothelial dysfunction. Thus, measurement of endothe-
lial function using RH-PAT may play an important role
as surrogate marker.
Miglitol, in comparison to other α-GIs such as voglibose
and acarbose, ameliorates the elevation in glucose shortly
after test meal loading. This quick action may be associated
with the unique pharmacokinetic properties of miglitol, i.e.,
rapid and almost complete absorption via the small intes-
tine [17,18,59]. Therefore, miglitol may have a powerful in-
hibitory effect against α-glucosidase without additional
adverse effects. It has been documented that α-GIs reduce
cardiovascular events in patients with impaired glucose tol-
erance, suggesting the importance of interfering with post-
prandial glucose fluctuation [19]. Dramatic changes in
endothelial function were observed with administration of
miglitol. Not only was PPHG improved, but so was post-
prandial endothelial dysfunction. Our study showed that
the glucose elevation between fasting and 60 minutes after
test meal loading is significantly associated with postpran-
dial endothelial function and that a reduction in the glucose
surge indicates improved endothelial function. However,
the effect of miglitol on endothelial function may not be to-
tally dependent on the glucose level. In fact, although
miglitol improved postprandial glucose levels measured at
both 60 minutes and 120 minutes, endothelial function im-
proved only between 60 minutes and 120 minutes. The
below-baseline endothelial function at 60 minutes may berelated to the glucose surge, but this decreased endothelial
function was restored to the baseline fasting level by 120
minutes even though the blood glucose level remained
high. Our data indicate that miglitol has a potent ameliora-
tive effect on endothelial function in patients with ACS and
PPHG, and the beneficial effects may not be totally
dependent on postprandial glucose swings, but may rather
be related to an additional pharmacologic mechanism of
action. Incretins, especially GLP-1, secreted as a result of
miglitol administration are thought to play an important
role in endothelial function [60,61]. Oral administration of
miglitol has been shown to increase GLP-1 secretion
[62-64], and GLP-1 upregulates NO production in endo-
thelial cells [65], independently improving vascular func-
tion [66]. Results of the present study suggest that
increasing GLP-1 and decreasing GIP might be important
to postprandial endothelial function and to the time
course of improvement. Moreover, the present study
showed that miglitol decreases hs-CRP, suggesting miglitol
suppresses inflammation and may act synergistically in
preserving endothelial function.
There were some limitations to the study. First, the
lack of significance in the levels of various markers could
have resulted from the relatively small patient groups.
The results should therefore be interpreted with caution.
Second, this was a very short-term follow-up study; the
long-term effects of miglitol on endothelial function and
ACS outcomes remain unknown. Third, in this study,
we excluded patients with type 1 DM and type 2 DM
who were treated with insulin and oral anti-DM agents
and patients with high HbA1c. We speculate that even if
such patients were included, we might have seen post-
prandial endothelial dysfunction related to postprandial
glucose elevation. Fourth, we excluded patients with
heart failure resulting from severe myocardial infarction,
because it has been reported that diabetes can lead to
heart failure after myocardial infarction, and moreover,
endothelial function may be impaired in patients with
heart failure [67-70]. Fifth, incretins, especially active
GLP-1, are unstable in vivo; they dissolve immediately.
Thus, it is difficult to investigate the clinical effects of
incretins. Furthermore, we assessed incretins in only a
few subjects, (8 PPHG-miglitol patients and 8 NGT pa-
tients), so the results are inconclusive.
Conclusions
Noninvasive assessment of fingertip endothelial function
may be clinically useful. In our patients with ACS, post-
prandial hyperglycemia rather than the fasting glucose
level appeared to affect postprandial endothelial func-
tion. Miglitol is effective against postprandial hypergly-
cemia, hyperinsulinemia, inflammation, and endothelial
dysfunction. Long-term follow-up studies are needed to
confirm these findings.
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